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Abstract 
Heroin is the main abused opioid, and is causing most drug use related deaths in the European 
Union and in the USA. New treatment strategies for heroin addiction are needed, and an 
alternative could be modulation of the enzymes involved in the heroin metabolism with the 
objective of reducing the rewarding effects of the drug. Different esterases have been shown 
to be involved in the metabolism of heroin. However, little is known about the importance of 
these enzymes in the heroin metabolism in organs other than blood. The aim of this study was 
to identify the esterases involved in heroin metabolism in liver, lung and brain tissue from rat 
and investigate whether modulation of these enzymes could decrease the effects of heroin in 
mice, by reducing the concentration of the active metabolite 6MAM. In vitro heroin 
metabolism studies were conducted in perfused rat liver, lung and brain tissue in the presence 
and absence of specific esterase inhibitors. This was followed by in vivo experiments in mice, 
where the effect of specific esterase inhibitors on the heroin metabolism and the heroin 
induced behavior were investigated. This was examined by combining a behavioral test and 
measurements of the heroin metabolites in blood and brain. LC-MS/MS was used to quantify 
heroin and heroin metabolites in the biological matrices. The results suggest that there are 
different enzymes metabolizing heroin in liver, lung and brain tissue. In liver and lung tissue 
mainly carboxylesterase is involved, while in brain mainly acetylcholinesterase and 
butyrylcholinesterase are involved. Administration of esterase inhibitors to mice did not affect 
the behavior as a result of reduced levels of 6MAM. Increased knowledge of the enzymes 
involved in metabolism of heroin is important and could lead to other pharmacokinetic 
treatment approaches. 
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Abbreviations 
6MAM   6-monoacetylmorphine 
AChE  Acetylcholinesterase 
BChE  Butyrylcholinesterase 
Benzylisatin 1-benzyl-1H-indole-2,3-dione 
BNPP Bis(4-nitrophenyl)phosphate 
Bw284c51 1,5-Bis(4allyldimethylammoniumphenyl)pentan-3-one dibromide 
CE Carboxylesterase 
Cmax  Maximum concentration 
ESI+  Positive electrospray 
Ethopropazine  
10-(2 Diethylaminopropyl)phenothiazine,10-[2-(Diethylamino)propyl]phenothiazine 
hydrochloride 
eV  Collision energy 
hCE-1  Human liver carboxylesterase 1 
hCE-2  Human liver carboxylesterase 2 
HPLC  High-performance liquid chromatography 
I.p. Intraperitoneal 
I.v. Intravenous 
Iso-OMPA Tetraisopropyl pyrophosphoramide 
kV  Capillary voltage 
L/h  Liters per hours 
LC-MS/MS  Liquid chromatography tandem  mass spectrometry 
LOD  Limits of detection 
LOQ  Limits of quantitation 
M3G  Morphine-3-glucuronide 
M6G  Morphine-6-glucuronide 
MRM  Multiple reaction monitoring 
Neostigmine 3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium bromide 
Rpm  Revolutions per minute 
Rt  Retention time 
S.c.  Subcutaneous 
SEM  Standard error mean 
UDPGA Uridine 5'-diphosphosphate-glucuronic acid 
UGT Uridine 5'-diphosphate- glucuronosyltransferases 
V  Voltage 
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1. Introduction 
1.1 Heroin addiction 
Opium is the dried latex obtained from the opium poppy (Papaver somniferum, figure 1.1). 
The use of opium is ancient, and through the centuries it has been used in religious rituals as 
well as for medical purposes [1]. In modern medicine drugs derived from opium are widely 
used as pain relievers. These drugs are called opioids and include morphine, codeine and 
oxycodone. In 1874 the English chemist A.C Wright attempted to develop a new drug similar 
to morphine without its addictive effect [2]. Rather he synthesized heroin, which has an even 
stronger addiction potential as well as a more potent reinforcing and analgesic activity 
compared with morphine [3]. This has led heroin to be the main abused opioid, causing most 
drug use related deaths in the European Union [4] and in the USA [5]. Over the last decade, 
Norway has had approximately 50 annual deaths per million citizens, of which about 80% are 
due to heroin overdoses. Thus, Norway is one of the countries in Europe with the highest 
narcotic related death rate [4, 6, 7]. 
 
 
Figure 1.1 - Opium poppy (Papaver somniferum) 
 
Heroin addiction is associated with a multitude of health and social problems, often leading to 
physical dependence and severe withdrawal symptoms. Heroin dependent drug users 
experience social implications and economic problems which lead to a lower quality of life 
compared to that of the general population [4]. Injection of heroin increases the risk of fatal 
overdose and transmission of blood-borne diseases such as HIV/AIDS as well as Hepatitis B 
and C [5, 8].  
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Various treatments are available for opioid dependence. Substitution therapy with opioid 
receptor agonist such as methadone and buprenorphine is currently the predominant 
alternative in Europe [4]. These pharmaceuticals bind to opioid receptors and decrease the 
effects of administration of heroin [9, 10]. However, by having the same mode of action as 
heroin, opioid agonists are themselves susceptible to abuse and overdoses. This typically calls 
for tight regulation as well as comprehensive administration, as the opioid agonists have 
limited duration of action [11]. 
 
Another class of drugs used in treatment are opioid receptor antagonists, like naltrexone, 
which successfully block opioid receptors, but have no stimulatory effect [12]. Compliance 
with antagonist use is generally low [11], which may be caused by their ability to also bind 
the body’s endogenous opioids causing a negative emotional effect in the patient [13].  
 
1.2 Pharmacology of heroin 
Heroin (3,6-diacetylmorphine) is a semi-synthetic opioid synthesized from morphine. The 
most common routes of administration of heroin are by injection as well as inhalation by 
vaporization or smoking [4, 14, 15]. The first-pass metabolism of the liver is avoided by both 
these administration routes [16]. Intravenous injection provides immediately onset of 
euphoria, while peak effects usually are felt within 10 to 15 minutes when heroin is inhaled 
[16].  
 
The physical effects of heroin are euphoria and pain relief, and are caused by binding to µ-
opioid receptors in the brain [17]. Activation of these opioid receptors increases the levels of 
the neurotransmitter dopamine by increasing the firing rate of dopaminergic neurons in the 
nucleus accumbens [18, 19]. This increase in dopamine release is believed to establish and 
reinforce the habit of drug abuse [20, 21].  
 
Normally endogenous opioid peptides like endorphins and enkephalins bind to µ-opioid 
receptors and initiate the release of dopamine [22]. The function is to reward behaviors 
essential for survival and evolutionary success, such as eating, drinking, having social 
interaction and sex [23]. Heroin acts much more strongly than natural rewards on these neural 
circuits, and also bypasses the feedback mechanisms normally controlling dopamine release 
in nucleus accumbens [24, 25]. The excessive release of dopamine caused by repeated drug 
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use may lead to several physiological processes, including up and down regulation of 
numerous genes which eventually leads to neuroadaptations [24]. Addiction to heroin is hence 
believed to be caused by repeated self-administration of the drug producing enduring 
adaptions in the neurotransmitter systems of the brain, leaving addicts vulnerable to relapse 
[23, 26].  
 
1.3 Metabolism of heroin 
After administration heroin is rapidly deacetylated to 6-monoacetylmorphine (6MAM), then 
further metabolized into morphine, morphine-3-glucuronide (M3G) and morphine-6-
glucuronide (M6G) [3]. This reaction is showed in figure 1.2.  
 
 
Figure 1.2 - The metabolism of heroin to 6MAM, morphine, M3G and M6G 
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The metabolism of heroin to 6MAM occurs primarily in the periphery [3, 27, 28]. This causes 
high blood levels of 6MAM which readily crosses the blood-brain barrier and binds to the  
µ-opioid receptors in the brain. Opioid receptors are stereo-specific, and heroin shows a lower 
µ-opioid receptor affinity than its metabolites [17, 29]. Hence heroin is behaving as a pro-
drug, and 6MAM mediates its early acute behavioral effects, at least in mice [27]. 
Additionally morphine contributes to these effects, but to a lesser degree due to lower levels 
and slower accumulation in brain [30].  
 
Heroin has a short half-life, between 1.3 and 7.8 minutes in human blood [28] and between 2 
and 5 minutes in mice blood [3]. 6MAM has a somewhat longer half-life than heroin, 
estimates ranging from 5.4 to 52 minutes in human blood [28]. 
 
In the body the hydrolysis of heroin and 6MAM is thought to be catalyzed by different types 
of esterases as well as non-enzymatically [28, 31]. Morphine is further metabolized mainly in 
the liver by glucuronidation to the inactive metabolite M3G and the active metabolite M6G 
[32]. However, in rodents, no or only small traces of M6G is produced [33]  The 
glucuronidation to the  - and  -positions of morphine is cataly ed by the en yme uridine    -
diphosphate- glucuronosyltransferases (UGT) [34]. 
 
1.4 Esterases capable of heroin metabolism 
Enzymes belonging to two distinct families within higher eukaryotes are known to metabolize 
heroin: cholinesterases and carboxylesterases [28]. Both families are phase-I drug 
metabolizing enzymes [35, 36].  
 
Cholinesterases are esterases that catalyze the hydrolysis of esters of choline. There are two 
known cholinesterases; acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)  [37]. 
Both enzymes are capable of hydrolyzing heroin [31]. 
 
The main function of AChE (EC 3.1.1.7) is to catalyze the hydrolysis of the neurotransmitter 
acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron 
to return to its resting state after activation [38]. In addition the enzyme have some non-
catalytic functions, such as involvement in cell adhesion and proliferation [39]. AChE is 
mainly found in neuromuscular junctions and in neural synapses, but also in the blood on red 
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blood cell membranes [40]. The enzyme is one of the fastest and most efficient enzymes 
known [41], each molecule of AChE degrades about 25000 molecules of acetylcholine per 
second [42]. This reaction is under normal conditions limited solely by the rate of 
acetylcholine diffusion into the gorge of the enzyme [39]. 
 
BChE (EC 3.1.1.8) is produced in the liver and primarily found in the plasma [43]. BChE is 
also present in the brain, where it accounts for about 10% of total brain cholinesterase 
activity, whereas AChE accounts for the residue [44]. BChE is less specific than AChE and 
capable of hydrolyzing a broad spectrum of structurally different substrates [37]. The function 
of this enzyme is therefore thought to be metabolism of various xenobiotics [45]. BChE also 
acts as a scavenger of many natural and synthetic anticholinesterase compounds, eliminating 
them before they reach AChE where they could cause serious neural dysfunction [46]. 
Humans lacking functional BChE appear healthy, which suggests that this enzyme is not 
essential for normal physiological functions [47]. 
 
Comparison of the structure of AChE and BChE shows extensive similarities in protein 
sequences and in molecular forms. AChE and BChE have more than 50% identical amino 
acids, have almost the same backbone structure as well as similar protein folding [48]. 
 
The third enzyme known to metabolize heroin is carboxylesterase (CE; EC 3.1.1.1). CE 
catalyze the hydrolysis of many clinically useful drugs as well as the narcotic cocaine [49], 
and is considered to be an important detoxification enzyme in mammals [50]. CE is mostly 
expressed in tissues likely to be exposed to xenobiotics, including the liver, lung, small 
intestine and kidney [51]. In humans, two CEs, hCE1 and hCE2, are important mediators of 
drug metabolism. Both are expressed in human liver, but the amount of hCE1 greatly exceeds 
hCE2 [52]. 
 
1.5 Inhibition of esterases 
The overall structure and catalytic activity of the two cholinesterases and CE are quite similar 
[53]. However, the details of the structure of the functional sub-domains differ. These 
differences affect the enzymes affinity to different substrates as well as their sensitivity 
against inhibitors [35, 39]. The use of enzyme inhibitors can therefore be utilized as a 
diagnostic tool to identify the different enzymes involved in a specific enzymatic reaction, 
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e.g. the deacetylation of heroin. Identification of the enzymes present in a tissue is commonly 
studied with techniques like immunohistochemistry or Western blotting. By the use of 
inhibitors, the importance of a specific enzyme in an enzyme reaction can be investigated at 
the same time. 
 
To understand how various inhibitors affect the metabolic capacity of esterases, it is necessary 
to know how these enzymes hydrolyze their substrates. Each subunit of these esterases has 
their active site located in a gorge that penetrates approximately halfway into the enzyme. 
Kinetic and structural studies have shown that the different esterases have similar functional 
sub-domains within this gorge [45, 48, 54]. A peripheral anionic site is located at the entry of 
the gorge. When a substrate binds to this site, it triggers a conformational change of the active 
site, allowing the substrate to slide down the gorge. There the substrate binds to the active 
site, called acyl binding site, and is then hydrolyzed in a two-step reaction. The product then 
disassociates, and the enzyme is ready to catalyze a new reaction [45, 54, 55]. In figure 1.3 
the structure of the active site of BChE is illustrated. 
 
 
 
Figure 1.3 - The structure of the active site of BChE [45] 
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Enzyme inhibitors affect enzyme reactions by binding to the enzymes and decreasing their 
activity. A large number of esterase inhibitors have been discovered as well as synthesized. In 
the following section the enzyme inhibitors used in this master thesis will be presented. These 
inhibitors were chosen based on their documented use in tissue localization of cholinesterases 
[56-59] and CE [60] and their known tolerance in animal in vivo experiments [61-63]. 
 
The general cholinesterase inhibitor neostigmine (figure 1.4.) is a carbamate [64, 65]. 
Multiple studies show that it does not affect CE at concentrations up to at least 1 mM [66, 67]. 
Neostigmine is used as a therapeutic agent, including in anesthesia, to reverse the 
neuromuscular blockade produced by neuromuscular blockers [68]. Neostigmine is not lipid 
soluble, hence it does not cross the blood-brain barrier [69]. Neostigmine binds to the active 
site of the enzyme, and due to its structure it has great binding strength and is therefore 
resistant to hydrolysis [64]. 
 
Figure 1.4 – Neostigmine 
 
BW284c51 (figure 1.5) is a bisquaternary ammonium compound and a highly specific 
inhibitor of AChE [70, 71]. The inhibitor has been shown to have approximately 347-fold 
more selectivity towards AChE than BChE in vitro [39]. The preference of BW284c51 
towards AChE is due to the presence of specific amino-acid residues in the active catalytic 
site and anionic site of the enzyme [72, 73].  
 
 
Figure 1.5 - BW284c51 
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Ethopropazine (figure 1.6.) is a phenothiazine derivative and a specific BChE inhibitor, which 
has shown an approximately 1800-fold preference for BChE compared to AChE [73]. 
Ethopropazine has been in clinical use in the treatment of Parkinson’s disease [74]. Due to 
different amino acids in the active gorge of AChE and BChE, the volume of the gorge of 
BChE is larger compared to AChE. This causes the specificity of ethopropazine towards 
BChE [75-77]. 
 
Figure 1.6 - Ethopropazine HCl 
 
Iso-OMPA (figure 1.7) is an organophosphate and is found to inhibit BChE more effectively 
than AChE [78]. It has been shown to be approximately 2700-fold more selective towards 
BChE than AChE in vitro [39]. The larger active gorge of the enzyme is the cause of the 
specificity of iso-OMPA towards BChE. Even though iso-OMPA often is considered being a 
specific BChE inhibitor [58, 79, 80], it has shown some activity towards CEs as well [81-84].  
 
 
Figure 1.7 - Iso-OMPA 
 
BNPP (figure 1.8) is an organophosphate and has been widely used as a specific CE inhibitor 
[60, 85]. However, some studies claim that due to the structure homology between CE and 
other esterases, organophosphates like BNPP may inhibit many different enzymes, including 
CEs, AChE and BChE [49, 86].  
18 
 
 
 
Figure 1.8 - BNPP 
 
Benzylisatin (figure 1.9) is a recently synthesized inhibitor of mammalian CEs [49]. This 
inhibitor is based on the structure of benzil (diphenylethane-1,2-dione), a known potent 
inhibitor of hCE1 and hCE2 [87]. Benzylisatin has not shown activity towards cholinesterases 
up to 100 µM. It is possible that benzylisatin will be better tolerated in vivo than benzil 
because it has a more similar structure to drugs that are already in clinical use [49].  
 
Figure 1.9 - Benzylisatin 
 
The inhibition mechanism of these six inhibitors is mainly competitive, and is caused by 
blockade of the active gorge. The different inhibitors accomplish this by binding to amino 
acids that line and/or form the active gorge of AChE, BChE and CE [35, 39]. Neostigmine, 
BW284c51, ethopropazine and benzylisatin inhibit the enzyme reversible, reducing the 
reaction rate to minutes rather than microseconds [49, 64, 73, 77]. Iso-Ompa and BNPP are 
irreversible inhibitors, which means that the enzyme is permanently inactivated. These 
inhibitors are both organophosphates and acts by phosphorylation of the active site of the 
enzyme [88, 89]. 
 
When using enzyme inhibitors to study the importance of different enzymes in a specific 
enzymatic reaction, the inhibitor used should be highly specific. This means that it should 
show significantly higher activity towards the enzyme of interest compared to other enzymes. 
In this case this is difficult to achieve, due to the fact that these esterases demonstrate 
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considerable amino acid and structural homology. Compounds that are marketed and have 
been used and described in numerous studies as specific esterase inhibitors may inhibit 
several esterases [49]. The specificity of the described esterase inhibitors is dependent on their 
concentration, since they are mainly competitive inhibitors [39]. Hence a lower binding 
affinity could be overcome by higher inhibitor concentration. 
 
1.6 Animal research and ethics 
Animal models are often used to predict the metabolic behavior of compounds in humans, and 
mice and rats are among the most commonly used test species. This is a consequence of the 
many practical advantages that these species possesses, as well as similar physiology to 
humans [90, 91]. Important physiological parameters, such as body temperature, hematocrit 
and serum albumin concentrations, are relatively conserved among rats, mice and humans 
[92]. Functional counterparts of almost all human genes also exist within the murine genome 
[93]. 
 
While significant advances in our understanding of drug metabolism have been derived from 
studies in rodent models, there are some major limitations to the use of laboratory animals as 
models for human drug metabolism. Body size and weight affect the pharmacokinetic 
parameters of xenobiotics across species. As a consequence of differences in body size and 
weight, the relative amount of hepatic enzymes is higher in small animals than in humans 
[90]. Blood circulation time correlates with total body weight, indicating that smaller animals 
eliminate drugs more rapidly than humans [94]. There are also interspecies variations in the 
expression and activities of drug metabolizing enzymes [90]. Extrapolation of data across 
species should therefore be done with care.   
 
The C57BL/6 mouse strain and the Sprague-Dawley rat strain used for the studies in this 
master thesis were selected for their known sensitivity for heroin, and for comparison to 
previous studies performed in the same strains at the Norwegian Institute of Public Health 
[27, 30, 33, 95] 
 
The research presented in this master thesis could not have been conducted without the use of 
animals. Animal research in Norway is regulated by the animal rights law given by the 
Ministry of Agriculture and Food. When using animals for research, alternatives must always 
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be considered and used if possible. The number of animals should also be minimized to the 
absolute requirement. The possible suffering of the animals must be weighed against the 
probable gain in each study, and the level of pain must be minimized. At the Norwegian 
Institute of Public Health all the necessary approvals for conducting animal research were 
obtained. 
 
1.7 Aim of the study 
Various esterases have been shown to be involved in the metabolism of heroin [28,  1, 9 , 
97]  Studies concerning heroin metabolism in blood have been carried out previously [ 1, 98, 
99], but there is little knowledge about the importance these esterases have in the heroin 
metabolism in other tissues  Three organs are of special interest due to their relevance in 
heroin metabolism: the brain, the liver and the lungs  The effect of heroin is exerted in the 
brain, the liver has a key role in the general xenobiotic metabolism, while the lungs are of 
interest because inhalation is a common administration route of heroin  
 
The hypothesis of this master thesis was that there are distinct en ymes metaboli ing heroin 
in brain, liver and lung  The first objective was therefore to identify the esterases involved in 
the heroin metabolism in isolated rat organs  The second objective was to test whether it 
would be possible to decrease the en ymatic conversion of heroin to  MAM in a mice model, 
and thereby reduce the physiological effects of the drug  These objectives were investigated 
by doing metabolism studies in vitro, inhibitor studies in vitro and in vivo and a behavior test 
in mice   
 
A more detailed understanding of heroin metabolism could be utili ed to develop new 
treatment strategies for heroin dependence  This is needed, since all present treatment of 
heroin addiction is associated with frequent relapses and is often unsuccessful [11]  
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2. Materials and methods 
2.1 Chemicals 
       Table 2.1 - Chemicals 
Chemical Specifications Supplier 
BNPP Bis(4-nitrophenyl)phosphate Sigma Aldrich, 
Germany 
BW284c51 1,5-Bis(4allyldimethylammoniumphenyl)pentan-
3-one dibromide  
Sigma Aldrich, 
Germany 
Ethopropazine 
hydrochloride 
10-(2 Diethylaminopropyl)phenothiazine, 10-[2-
(Diethylamino)propyl]phenothiazine 
hydrochloride 
Sigma Aldrich, 
Germany 
Heroin 3,6-diacetylmorphine hydrochloride Lipomed AG, 
Switzerland. 
Iso-OMPA Tetraisopropyl pyrophosphoramide 
 
Sigma Aldrich, 
Germany 
Ketalar ® 
 
Ketamine, 10 mg/ml Pfizer, Norway 
N-Benzylisatin 1-benzyl-1H-indole-2,3-dione Sigma Aldrich, 
Germany 
Neostigmine 
bromide 
3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-
trimethylanilinium bromide 
Sigma Aldrich, 
Germany 
Rompun
®
 Xylazine hydrochloride, 20 mg/ml Bayer 
Healthcare, 
Norway 
Titriplex
®
 III Ethylenedinitrilotetraacetic acid disodium salt 
dihydrat 
Merck 
Millipore, 
Germany 
 
All other chemicals were supplied by standard commercial suppliers. 
 
 
22 
 
 
2.2 Animals 
Male Sprague-Dawley rats from Taconic (Bomholt, Ejby, Denmark), age 8-10 weeks and 
weight about 200-250 g, were used in the in vitro experiments. 26 male C57BL/6J-Bom mice 
from Taconic (Bomholt, Ejby, Denmark), age 7-8 weeks and weight between 21.7 to 27.0 g, 
were used in the in vivo experiments. The animals were kept in the animal facilities at the 
Norwegian Institute of Public Health at 22 ± 1°C, 50 ± 10% humidity with light period 7:00 
AM–7:00 PM. Rats were housed two per cage, mice were housed seven to eight per cage. 
Animals arrived at least 5 days before the experiments. Commercial rat/mice pellets and water 
were available ad libitum. 
 
The Animal Research Authority for the use of animal subjects approved the experimental 
protocols of the studies. Procedures and handling of all animals used in these experiments 
were carried out in agreement with the Norwegian Animal Welfare Act. 
 
2.3 Preparation of rat organs for in vitro experiments 
Non-perfused liver: Rats were sacrificed by decapitation. Liver was collected, rinsed in NaCl 
and immediately placed on ice. The liver was homogenized in Tris/Krebs-buffer (10 mM Tris, 
140 mM NaCl, 5 mM KCl, 5mM NaHCO3, 1 mM MgCl2, 1.2 mM Na2HPO4, 10 mM 
glucose, 1.2 mM CaCl2, pH 7.4) with a teflon/glass homogenizer (2 ml/g tissue). The 
homogenate was then diluted 1:1 in Tris/Krebs-buffer. For experiments on fresh tissue the 
tissue material was kept on ice and used within 2 hours after harvest. The rest of the tissue 
was frozen in liquid N2 and stored at -80°C. The non-perfused livers were used for comparing 
heroin metabolism in frozen and fresh tissue. 
 
Perfused organs: Rats were anaesthetized using a mixture containing Ketalar
®
 (100 mg/kg) 
and Rompun
®
 (10 mg/kg) administered intraperitoneally (10 ml/kg). While being ventilated 
through a tracheal catheter, the rats were perfused (30-32 ml/min) via the left heart chamber 
with a PBS buffer (0.01 M PO4
3-
, 0.0027 M KCl and 0.137 M NaCl, pH 7.2 - 7.6). The organs 
were perfused for 10-15 min. Brain, liver and lungs were removed and homogenized (2 ml/g 
tissue) in ice-cold PBS buffer using a teflon/glass homogenizer. The lungs were minced with 
scissors and blotted on filter paper before homogenization. The tissues were frozen in liquid 
N2 and then stored at -80°C. The perfused organs were used in the heroin metabolism 
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experiments and enzyme inhibitor experiments. The perfusion procedure was done in 
cooperation with the animal department at the Norwegian Institute of Public Health.  
 
2.4 In vitro heroin metabolism in rat organs 
The heroin used in the in vitro experiments was dissolved in 0.9% NaCl maximum 7 days 
prior to the experiments and stored in refrigerator at 4˚C  Experiments were conducted 
showing that heroin is stable in this solution for at least 7 days (unpublished results). All 
incubation times, concentrations and conditions for the in vitro experiments were chosen 
based on earlier published studies [27, 30] and pilot experiments conducted as a part of this 
master thesis. 
  
2.4.1 Heroin metabolism comparing fresh and frozen liver 
Non-perfused liver homogenate (110 μl) was transferred to plastic-tubes kept in a water bath 
at  7˚C and pre-incubated for 15- 0 min  12 μl heroin solution  was added to each tube (final 
concentration 0 4 μM)  The tubes were briefly mixed and placed back in the water bath  The 
samples were incubated for a pre-specified time (0.05, 0.25, 0.5, 1, 3, 5, 10 and 30 min). Then 
78 μl ice-cold 13 mM ammonium format buffer (pH 3.1; final concentration 5 mM) with 
sodium fluoride (final concentration 2 mg/ml) was added to stop the enzymatic reaction. The 
tubes were immediately mixed and quickly frozen in liquid N₂. The tissue samples were 
placed in a deep-freezer at -80˚C before sample preparation and analyses by LC-MS/MS the 
same day (see section 2.7-2.8). 
 
2.4.2 Heroin metabolism in liver, lung and brain 
The studies of in vitro heroin metabolism in perfused liver, lung and brain were conducted as 
described in section 2.4.1 with some modifications. Tissue homogenate was diluted 1:1 in 
PBS buffer and then 100 µl and 10 µl PBS were added to the tubes. The incubation time was 
0.05, 0.25, 0.5, 1.5, 5, 10 and 30 min for liver homogenate and 0.05, 0.5, 1, 3, 5, 10 and 30 
min for lung and brain homogenates. The total protein concentration in each of the samples 
was measured as described in section 2.9 to be 0.454 mg ± 0.029 in liver, 0.138 mg ± 0,014 in 
lung and 0,346 mg ±  0,033 in brain (mean ±SEM). 
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2.4.3 Inhibition of heroin metabolism in liver, lung and brain 
The enzyme inhibitor experiments in perfused liver, lung and brain were conducted as 
described in 2.4.1, with some modifications. The tissue homogenate was first diluted 1:1 in 
Tris/Krebs-buffer and then 1100 µl tissue homogenate was added to 1300 µl Tris/Krebs-
buffer. Then 60 µl tissue homogenate (liver, lung, brain) was added to the tubes. Before 
adding heroin, 40 µl NaCl and 10 µl enzyme inhibitor were added to each plastic-tube to a 
final concentration of 10 µM or 100 µM (see table 2.2). Then the samples were pre-incubated 
for 15-30 min. The incubation times after addition of heroin were 3 min for liver, 60 min for 
lungs and 30 min for brain. These time points were chosen based on the data from the time 
curves from the in vitro heroin metabolism in perfused organs. The total protein concentration 
in the samples was measured as described in section 2.9 to be 0.245± 0,015 in liver, 0.75± 
0.008 in lung and 0.187± 0,018 in brain (mean ± SEM). 
 
          Table 2.2 – Enzyme inhibitor concentrations 
Enzyme inhibitor Final concentration 
BW284c51 10 µM and 100 µM (dissolved in NaCl 0.9%) 
Iso-OMPA 10 µM and 100 µM (dissolved in NaCl 0.9%) 
BNPP 10 µM and 100 µM (dissolved in NaCl 0.9%) 
Neostigmine 10 µM 100 µM (dissolved in NaCl 0.9%) 
Ethopropazine 10 µM 100 µM (dissolved in dH2O) 
Benzylisatin 10 µM 100 µM (dissolved in ethanol) 
 
 
2.5 In vitro heroin metabolism and sample preparation  in microsomes, 
cytosol and s9-fraction 
Different liver fractions, s9-fraction, microsomes and cytosol from male Sprague-Dawley rats 
were purchased from Life Technologies (Frederick, MD, USA). See table 2.3 for further 
explanation of the different fractions. 
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Table 2.3 – Explanation of the different liver fractions used [100] 
Liver fraction  
S9 A supernatant fraction obtained from liver homogenate by centrifuging liver 
homogenate at 10,000g. Contains both microsomes and cytosol.  
Microsomes Further centrifugation of the s9 fraction at 100,000g yields the endoplasmic 
reticulum-derived microsomes. 
Cytosol The cytosol is the portion of the cytoplasm not contained within membrane-
bound organelles. 
 
130 µl NADPH regeneration solution (1.3 mM NADP
+
, 3.3 mM glucose 6-phosphate, 
0.4U/ml glucose 6-phospate dehydrogenase, 3.3 mM MgCl2) was added to separate plastic-
tubes kept in a water bath, at  7˚C  10 µl heroin was added (final concentration 0   µM) and 
the samples were mixed well. 10 µl s9, microsomes or cytosol fraction (protein concentration 
20 mg/ml) were added and the samples were incubated for a given time (0, 1, 3, 5, 10, 30 and 
60 min). The reaction was then terminated by adding 20 µl 1 M formic acid to each tube and 
vortexing for 1 min. 30 µl internal standard was added before the samples were centrifuged 
for 5 min at 14  00 rpm (11  00g, 4˚C,   min). The supernatants were transferred to 
autosampler vials. The standards and controls were prepared by mixing 100 µl 
standard/control, 70 µl distilled water and 30 µl internal standard. 
 
2.6 Enzyme inhibitor studies in vivo 
2.6.1 In vivo exposure 
The mice (n=26) were injected intraperitoneally (i.p.) with saline or an enzyme inhibitor (all 
dissolved in 0.9% NaCl): BNPP (100 mg/kg), BW284c51 (1 mg/kg) or Iso-OMPA (10 
mg/kg). The injection volume was 0.1 ml/10 g mouse for all solutions. Heroin (2.5 µmol/kg) 
was injected subcutaneous (s.c.) or intravenously (i.v.) in a volume of 0.05 ml/10 g mouse. 
The experiment was done in cooperation with supervisors at the Norwegian Institute of Public 
Health who injected the mice. 
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2.6.2 Locomotor studies 
Locomotor activity was tested in a VersaMax optical animal activity monitoring system 
(AccuScan Instruments, Inc., Colombus, OH, USA). The activity chambers were divided into 
four separate quadrants (20 cm x 20 cm) and two mice were tested simultaneously in each 
chamber, using nonadjacent quadrants. Locomotor activity was registered with a grid of 
infrared beams. Based on previous experience in our lab [27, 101], distance travelled 
(cm/5min) was used as an expression for locomotor activity. The mice were injected with 
enzyme inhibitor and then habituated in their respective activity chamber for 1 hour. Then the 
mice were injected with heroin (2.5 µmol/kg) s.c. or i.v. The heroin was dissolved in 0.9% 
NaCl the same day as the experiment. The mice were immediately returned to their respective 
locomotor chambers where the activity was measured for 20 min.  The locomotor activity test 
was performed as described in Andersen et al. [27] with some modifications. Drugs were 
administered in one room, while the locomotor activity test took place in another. 
 
2.6.3 Harvesting of mice blood and brain 
Immediately after measurement of locomotor activity, the mice were anaesthetized with 
isoflurane before blood samples (~500 µl) were obtained by heart puncture (t=25 min), using 
a syringe containing 80 µl of sodium fluoride (final concentration 4mg/ml) dissolved in 
heparin (100 IU/ml). 
 
The blood was diluted 1:1 in ice-cold 5 mM ammonium format buffer, pH 3.1, and 
immediately frozen in liquid N2. After blood sampling, the brain (except cerebellum) was 
quickly removed, washed in ice-cold 0.9% NaCl and blotted on a filter paper. Then the brain 
was homogenized (2 ml/g tissue) in 5mM ammonium format buffer, pH 3.1 with sodium 
fluoride (4mg/ml) and diluted 1:1 in ice-cold 5 mM ammonium format buffer before being 
frozen in liquid N2. Ice-cold acidic buffer was used to dilute the blood samples and to 
homogenize brain tissue, since heroin has been shown to be most stable at low temperatures 
and low pH (Barrett et al., 1992). Sodium fluoride (final concentration 2 mg/ml) was used to 
inhibit plasma esterase activity, thereby stabilizing the amount of heroin and 6-MAM (Brogan 
et al., 1992). All samples were stored at -80°C until analyzed by LC-MS/MS. Heroin is 
rapidly metabolized in biological tissues [102], especially in blood [103], and therefore the 
blood samples were analyzed the same day, and the brain samples were analyzed the 
following day. 
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2.7 Preparation of samples from rats and mice prior to LC-MS/MS 
Preparation of samples was performed as described in Karinen et al. (2009) with 
modifications as described below. 100 μl standards and controls were added to separate 
plastic tubes and placed on ice. Then 100 μl tissue homogenate/blood was added to all 
standards and controls. For in vitro heroin metabolism comparing fresh and frozen liver rat 
liver was used in standards and controls. For in vitro pharmacokinetics and enzyme inhibitor 
experiments human blood was used in the standards and controls. For the in vivo experiments 
rat brain and rat blood were used in the standards and controls for the respective organ. 
 
Samples from the experiments were gently thawed on ice. 50 μl internal standard mixture was 
added to all tubes and mixed well. Thereafter 500 μl ice-cold acetonitrile/methanol (85:15) 
was added and the tubes were mixed well for 10-15 sec. All samples were capped and placed 
in the deep-freezer (-20˚C) for minimum 10 min before being centrifuged at 4500 rpm 
(4700g) at 4°C for 10 min. The organic phase was transferred to 5 ml glass tubes and 
evaporated to dryness in a water bath under a stream of nitrogen (7 bar, 40˚C,  0 min)  100 μl 
cold 5 mM ammonium format buffer with acetonitrile (97:3), pH 3.1, was added to all tubes 
before they were centrifuged at 4500 rpm (3800g) at 4°C for 10 min. The supernatant was 
transferred to 0.3 ml autosampler vials.  
 
2.8 LC-MS/MS analysis 
The presence of heroin and the heroin metabolites 6MAM, morphine and M3G in the samples 
were analyzed using liquid chromatography tandem mass spectrometry (LC-MS/MS). 
Reversed phase chromatography in a XTerra ® MS C18 column (Waters Corp., Milford, MA, 
USA) with an acidic mobile phase combined with positive electrospray (ESI+) detection was 
used with a flow rate of 0.2 ml/min. This method combines the separation capabilities of 
HPLC with the detection capabilities of MS and is a selective and sensitive analysis method 
well established at the “Division for Forensic Sciences” at the Norwegian Institute of Public 
Health [104]. For more detailed information on the LC-MS/MS conditions, see appendix 
section 7.2. 
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2.9 Determination of protein levels 
The amount of protein in the different tissue homogenates was determined as described by 
Lowry et al. [105]. In this method a color reaction between phosphomolybdic ions and 
proteins will appear if the proteins are pre-exposed to copper ions (Cu
2+
) in an alkaline 
environment. 
 
4 µl tissue homogenate (0.17 g/ml) was mixed with 196 µl dH2O. The reaction was initiated 
by adding 1 ml application solution (2% Na2CO3 in 0.1 M NaOH, 0.5% CuSO4x5H2O, 1% 
K(Na)tartrate; 98:1:1). Each sample was mixed well. 
 
After 10 min the reaction was stopped by adding 100 µl “stop reagent” (Folin-Ciocalteus 
reagent, dH2O; 1:1) and mixed well. Three parallels were made of each sample. The samples 
were placed on the bench for a minimum of 30 min before the absorbance was read at 750 nm 
by a spectrophotometer (Lambda 3; Perkin Elmer, Waltham, MA, USA). The concentrations 
of the standards for determination of protein levels are shown in table 2.4. 
 
Table 2.4 – Concentrations of standards for determination of protein levels 
Standard Concentration of BSA (dissolved in dH2O) 
Blind 0 µg 
Standard 1 1µg 
Standard 2 2,5 µg 
Standard 3 5 µg 
Standard 4 10 µg 
Standard 5 15 µg 
Standard 6 20 µg 
Standard 7 25 µg 
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2.10 Data analysis 
Data were analysed using SPSS Statistics 20.0; (SPSS Inc., Chicago, IL. USA). Data are  
presented as mean ± SEM unless otherwise stated. The pharmacokinetic software Kinetica 
v.5.1 (Thermo Fisher Scientific Inc., Waltham, MA, USA) was used to analyse the data from 
comparison of heroin metabolism in fresh and frozen liver and heroin metabolism in perfused 
organs. The mean values were calculated for each time point measured and the resulting data 
fed to Kinetica using a simple model for linear pharmacokinetics with three compartments 
(heroin -> 6-MAM -> morphine) and bolus as heroin administration method. The rate 
constants k (min
-1
) were estimated by Kinetica by fitting the first order differential equations 
generated by the model to the experimental data. Half-life (t1/2) was calculated from the 
corresponding parameters. For the comparison of heroin metabolism in fresh and frozen liver 
the calculated rate constant for heroin and 6MAM was tested separately for significance, 
comparing fresh and frozen liver by performing a t-test. For the heroin metabolism in 
perfused organs the calculated rate constant for heroin and 6MAM was analyzed separately 
and a comparison between the tissues was done by a univariate General Linear Model, 
followed by a Tukey’s post-hoc test. 
 
The opioid concentration data from the in vitro and in vivo enzyme inhibitor study were 
analyzed using a univariate General Linear Model. Heroin, 6MAM, morphine and M3G were 
analyzed separately, with inhibitors as a fixed factor. For the data from the in vitro inhibitor 
study, Tukey’s test was used as a post-hoc test. For the in vivo inhibitor study, a two-sided 
Dunnett's test was used as post-hoc test. The data from the locomotion studies was tested for 
significance by performing t-tests for each time point. 
 
P-values ≤ 0 0  were considered statistically significant  
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3. Results 
3.1 Comparison of heroin metabolism in frozen and fresh liver in vitro 
The heroin metabolism in fresh and frozen liver tissue was compared to evaluate whether 
frozen tissue could be used in metabolism studies. The metabolism of heroin (0.4 μM) in 
frozen and fresh liver homogenate from rats is presented in figure 3.1. 
 
The transition from heroin to 6MAM in frozen tissue was not significant different from fresh 
tissue [t(5)=1.179;p>0.05]. However the transition from 6MAM to morphine was significant 
slower in frozen tissue compared with fresh tissue [t=(5)6.619;p=0.01]. It was concluded that 
this difference was so minor that frozen tissue could be used in further experiments as 
discussed in the discussion section 4.1. 
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Figure 3.1. In vitro concentration of heroin, 6MAM and morphine in fresh and frozen liver 
homogenate from rats as function of time (min) after addition of heroin (0.4 μM). All values are 
presented as mean ± SEM, n=3-4. 
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3.2 Heroin metabolism in liver, lung and brain tissue in vitro 
The heroin metabolism in perfused liver, lung and brain tissue was measured and is presented 
in figure 3.2-3.4. The metabolism was measured for 30 minutes based on pilot experiments 
which showed that within this time the concentration of heroin was approaching zero in all 
tissues. 
 
The heroin metabolism in liver homogenate after addition of heroin (0.4 μM) is presented in 
figure 3.2. Heroin concentrations decreased rapidly in liver while 6MAM concentrations 
increased fast. The concentration of heroin reached zero after 5 min. At about 1.5 min 6MAM 
reached maximal concentration (Cmax), and then started descending reaching 0.31 nmol/g at 
30 minutes. At approximately 7.5 minutes, the concentration of morphine exceeded the 
concentration of 6MAM and continued rising throughout the experiment (30 min). 
 
Figure 3.2. In vitro concentration curves of heroin, 6MAM and morphine in rat liver homogenate as 
function of time (min) after addition of heroin (0.4 μM). All values are presented as mean ± SEM, n=4. 
 
The metabolism of heroin in lung homogenate is presented in figure 3.3 and in brain 
homogenate in figure 3.4 respectively. In lung the heroin concentration was measured to be 
0.12 nmol/g at 30 minutes. The concentration of 6MAM continued to increase up to 2.41 
nmol/g at 30 minutes.  In brain tissue the concentration of heroin reached zero at 30 minutes. 
Cmax of 6MAM was achieved after approximately 10 minutes and were stable up to 30 
minutes at approximately 2.26 nmol/g. In both tissues morphine increased slowly, reaching a 
concentration of 0.3 nmol/g in brain tissue and 0.13 nmol/g in lung tissue at 30 minutes. 
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Figure 3.3. In vitro concentration curves of heroin, 6MAM and morphine in rat lung as function of 
time (min) after addition of heroin (0.4 μM). All values are presented as mean ± SEM, n=4. 
 
 
Figure 3.4. In vitro concentration curves of heroin, 6MAM and morphine in rat brain homogenate as 
function of time (min) after addition of heroin (0.4 μM. All values are presented as mean ± SEM, n=4. 
 
There was found a significant difference in the reaction rate between the tissues in the 
transition from heroin to 6MAM [F(2,9)=85.693;p<0.001] and in the transition from 6MAM 
to morphine [F(2,9)=179.198;p<0.001]. Liver had a significant faster reaction rate compared 
to brain (p<0.001) and lung (p<0.001) in the conversion from heroin to 6MAM. Also in the 
conversion from 6MAM to morphine liver had a significant faster reaction rate compared to 
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brain (p<0.001) and lung (p<0.001). No significant differences in reaction rates were found 
between brain and lung (p>0.05). The half-life of heroin was calculated to be 1 min (±0.09) in 
liver, 4 min (±0.15) in brain and 6.5 min (±0.33) in lung (mean±SEM). 6MAM was calculated 
to have a half-life of 7.5 min (±0.54) in liver, 106 min (±9.62) in brain and 154 min (±27.04) 
in lung (mean±SEM). The morphine metabolites M3G and M6G were not detected in liver, 
brain or lung homogenate.  
 
3.3 Inhibition of heroin metabolism in liver, lung and brain tissue in vitro 
The effect of cholinesterases and CE inhibitors on heroin metabolism was tested in liver, 
brain and lung homogenate. Due to the solubility of the inhibitors, different controls were 
used for the different inhibitors; this is described in table 2.2 in the method section 2.4.3. The 
controls were not significant different from each other; hence solely the saline control is 
shown in the diagrams 3.5 and 3.6. 
 
3.3.1 Effect of cholinesterase inhibitors 
The effect on the heroin metabolism by the cholinesterase inhibitors BW284c51, neostigmine, 
ethopropazine and iso-OMPA was tested separately in vitro in liver, brain and lung 
homogenate. The results are shown in figure 3.5. 
 
In liver and lung homogenate the presence of 100 µM iso-OMPA significantly increased the 
concentration of heroin by 275% and 216% respectively compared to the control. Pre-
incubation with 100 µM iso-OMPA significantly decreased the concentration of 6MAM by 
16% in liver homogenate and 35% in lung homogenate compared to the control. Bw284c51, 
neostigmine, ethopropazine and 10 µM of iso-OMPA had no significant effect on the 
concentration of heroin or heroin metabolites in liver or lung homogenate. 
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Figure 3.5. Concentrations of heroin, 6MAM and morphine in liver- brain- and lung homogenate 
after addition of heroin (0.4 μM) in vitro in the presence of one of the cholinesterase inhibitors (10 µM 
or 100 µM); BW (BW284c51), ETZ (ethopropazine), Iso (iso-OMPA) and Neo (neostigmine). The 
incubation time was 3 min for liver tissue, 60 min for lung tissue and 30 min for brain tissue. Values 
significantly different from the control are indicated with asterisks (*p<0.05, **p<0.01, ***p<0.001). 
All values are presented as mean ± SEM, n=3-4. 
36 
 
In brain homogenate the concentration of heroin and morphine was significant different from 
the control in the presence of 10 µM and 100 µM BW284c51, neostigmine and 
ethopropazine. The heroin concentrations were increased by 23-69% while the morphine 
concentrations were decreased by 7-38% compared to control. Pre-incubation with iso-OMPA 
showed no significant effect on the concentration of heroin or heroin metabolites in brain 
homogenate.  
 
3.3.2 Effect of CE inhibitors 
The effect on the heroin metabolism by the CE inhibitors benzylisatin and BNPP was tested 
separately in vitro in liver, brain and lung homogenate. The results are shown in figure 3.6.  
In liver homogenate the presence of 100 µM benzylisatin significantly increased the heroin 
concentration by 295% and significantly decreased 6MAM concentration by 12% compared 
to the control. In the presence of 10 µM and 100 µM BNPP the concentration of heroin 
significantly increased by 267% and 592% respectively, while 6MAM significantly decreased 
by 23% and 45% respectively compared to the control. In addition the presence of 100 µM 
BNPP decreased the concentration of morphine significantly by 69%.  
 
In lung homogenate the presence of 100 µM of benzylisatin significantly increased the heroin 
concentration by 178% and significantly decreased 6MAM concentration by 28% compared 
to the control. The heroin concentration was also significantly increased by 125% compared 
to the control in the presence of 100 µM BNPP.  
 
The two CE inhibitors did not affect the concentration of heroin or heroin metabolism in brain 
homogenate.  
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Figure 3.6. Concentrations of heroin, 6MAM and morphine in rat liver- brain- and lung homogenate 
after addition of heroin (0.4 μM) in vitro in the presence of one of the CE inhibitors (10 µM or 100 
µM); Bn-isatin (benzylisatin) and BNPP. The incubation time was 3 min for liver tissue, 60 min for 
lung tissue and 30 min for brain tissue. Values significantly different from the control are indicated 
with asterisks (*p <0.05, **p<0.01, ***p<0.001). All values are presented as mean ± SEM, n =3-4. 
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3.4 Heroin metabolism in different liver fractions 
The metabolism of heroin was investigated in different liver fractions from rat; s9, 
microsomes and cytosol bought commercially. The aim was to investigate the cellular 
localization of the enzyme responsible for the heroin metabolism. The results are presented in 
figure 3.7.  
 
The heroin concentration was zero after about 5 minutes in the microsomes, 10 min in the s9 
and 60 min in the cytosol. 6MAM reached Cmax at 1 min in microsomes and then declined to 
zero at approximately 30 min. In s9 6MAM reached Cmax at 5 min and declined to 
approximately zero at 60 min. In cytosol the 6MAM concentration increased slowly, reaching 
a concentration of 0.41 µM at 60 min. 
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Figure 3.7.  Concentrations of heroin, 6MAM and morphine in rat microsomes, cytosol and s9 
fraction as function of time (min) after addition of heroin (0.4 μM). For time points 0-30 min in 
microsomes and 0-10 min in cytosol and s9, n= 2. These values are presented as mean ± SEM. For the 
time point 60 min in microsomes and 30 and 60 minutes in s9 and cytosol, n=1. 
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In the initial experiments, it was found that the total concentration of heroin and heroin 
metabolites (6MAM and morphine) in microsomes and s9 was severely reduced over time, as 
shown in figure 3.8. In both fractions the reduction was approximately 60% at 60 min. In 
comparison the total concentration of metabolites in cytosol was reduced approximately 7% at 
60 min. The morphine metabolites M3G and M6G were not detected. As a result of this 
finding, only a few experiments were conducted. Several control experiments were performed 
to try to find the cause of the reduction of total metabolites. This is further discussed in the 
discussion section 4.3.  
 
 
Figure 3.8.  Total concentration of heroin and heroin metabolites (6MAM and morphine) in rat 
microsomes, cytosol and s9 fraction at different time points (min) after addition of heroin (0.4 μM). 
For time points 0-30 min in microsomes and 0-10 min in cytosol and s9, n= 2. These values are 
presented as mean. For the time point 60 min in microsomes and 30 and 60 minutes in s9 and cytosol, 
n=1. 
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3.5 The effects of inhibition of heroin metabolism in vivo 
The effects on heroin metabolism and locomotor activity by pre-treatment with three esterase 
inhibitors were tested in vivo. Mice were pre-treated with either NaCl (0,9 %), BNPP (100 
mg/kg), BW284c51 (1 mg/kg) or iso-OMPA (10 mg/kg) prior to an injection with heroin (2.5 
μmol/kg) as described in method section 2.6.1. The locomotor activity of the mice was then 
tested to assess the effect of the inhibitors on the heroin induced behavioral response. 
Additionally, the concentration of heroin metabolites was measured in the blood and brain of 
the mice. The results are described in sections 3.5.1 and 3.5.2. 
 
3.5.1 Effects on locomotor activity 
The results from the locomotor activity test showed that injection of heroin stimulated 
locomotor activity after both s.c. administration (figure 3.9) and i.v. administration (figure 
3.10).  The mice pre-treated with NaCl reached maximal response at 15 min and 10 min after 
s.c. and i.v. administration of heroin respectively. When heroin was administered s.c. pre-
treatment with BW284c51 reduced the locomotor activity significantly at 10 min and 15 min, 
respectively [t=(4)5.429;p=0.006] and [t=(4)4.056;p=0.015]. However, the mice pre-treated 
with BW284c51 showed signs of cholinergic syndrome (whole body tremors and prostration), 
which affected the locomotor activity. This is further discussed in the discussion section 4.4. 
Pre-treatment with BW284c51 did not significantly affect the locomotor activity when heroin 
was administered i.v. (p >0.05). Pre-treatment with BNPP or iso-OMPA did not significantly 
affect the locomotor activity either for s.c. or i.v. heroin administration (p >0.05).  
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Figure 3.9. Locomotor activity expressed as distance travelled (cm) per 5 min, after administration of 
heroin (2.5 μmol/kg, s.c.) to mice pre-treated (i.p) with Iso-OMPA (10 mg/kg), BW284c51 (1 mg/kg), 
BNPP (100 mg/kg) or 0.9% NaCl. Values significantly different from the control are indicated with 
asterisks (*p<0.05, **p<0.01, ***p<0.001). All values are presented as mean ± SEM, n = 3. 
 
 
Figure 3.10. Locomotor activity expressed as distance travelled (cm) per 5 min, after administration 
of heroin (2.5 μmol/kg, i.v.) to mice pre-treated (i.p) with Iso-OMPA (10 mg/kg), BW284c51 (1 
mg/kg), BNPP (100 mg/kg) or 0.9% NaCl. All values are presented as mean ± SEM, n=3-4. 
 
 
** 
     * 
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3.5.2 Effects on concentrations of heroin metabolites in blood and brain 
The concentration of heroin metabolites in blood and brain is presented in figure 3.11 and 
3.12. The concentration of heroin was under the detection limit in both blood and brain. 
6MAM and morphine were present in both tissues.  M3G was abundant in blood, while 
present at much lower concentration in brain, which indicates a slow uptake of M3G to the 
brain.  
 
Figure 3.11 shows that after s.c. injection of heroin (2   μmol/kg) mice pre-treated with iso-
OMPA had a significant higher 6MAM concentration in both blood and brain compared to the 
control mice, respectively [F(3,8)=5.098;p=0,029, post hoc test;p=0.013] and 
[F(3,8)=5.538;p=0.024, post hoc test;p=0.011] . Compared to the control the increase in brain 
concentration was 68%, and the increase in blood concentration 124%.  After  i.v. injection of  
heroin (2   μmol/kg) presented in figure 3.12, pre-treatment with BNPP and iso-OMPA 
showed significant higher blood concentrations of 6MAM compared to the control, 
respectively [F(3,10)=19.617;p<0.001, post hoc test;p<0.001] and [F(3,10)=19.617;p<0.000, 
post hoc test;p=0.010] . Compared to the control the increase in blood concentration was 
92%, for BNPP and 86% for iso-OMPA.  Pre-treatment with BW284c51 did not have 
significant effects on the concentration of 6MAM, morphine or M3G in blood or brain  
(p >0.05). 
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Figure 3.11 Concentration of 6MAM, morphine and M3G in brain and blood after s.c. administration 
of heroin (2.5 µmol/kg) to mice pre-treated (i.p.) with Iso-OMPA (10 mg/kg), BW284c51 (1 mg/kg), 
BNPP (100 mg/kg) or 0.9% NaCl. Values significantly different from the control are indicated with 
asterisks (*p<0.05). All values are presented as mean ± SEM, n=3. 
 
Figure 3.12 Concentration of 6MAM, morphine and M3G in brain and blood after i.v. administration 
of heroin (2.5 μmol/kg) to mice pre-treated (i.p.) with Iso-OMPA (10 mg/kg), BW284c51 (1 mg/kg), 
BNPP (100 mg/kg) or 0.9% NaCl. Values significantly different from the control are indicated with 
asterisks (**p<0.01, ***p<0.001). All values are presented as mean ± SEM, n=3-4. 
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4. Discussion 
4.1 Comparison of heroin metabolism in frozen and fresh tissue 
Rat blood is known to contain esterases [96], and to be able to identify the esterase enzymes 
involved in metabolism of heroin in different organs, it is necessary to reduce the contribution 
of blood to this metabolism. Therefore the animals were perfused, and due to this being a 
comprehensive procedure, it was desirable to use frozen tissue in the experiments. Cold 
denaturation has been  documented for several proteins [106, 107] which could be caused by 
critical stressors to which proteins are exposed to during freezing, for example low 
temperature and the formation of ice. This could lead to conformational changes and loss of 
biological activity [108]. How esterases in liver and other tissues are affected by 
freezing/thawing is not well studied. The observed effects seem to differ between species 
[109-112] and one study conducted in human liver samples showed decreased activity of CE 
after freezing [113]. Research on the specific enzyme of interest appears to be needed before a 
conclusion may be drawn. Consequently, heroin metabolism in frozen liver was compared 
with fresh liver tissue. The results showed that there was no difference in the transition from 
heroin to 6MAM, but that the metabolism from 6MAM to morphine was somewhat slower in 
frozen liver compared with fresh liver. However, the reduction of enzyme activity was limited 
in extent and relatively constant from one sample to the next. This indicates that the use of 
frozen tissue was appropriate, since the focus in this thesis was on comparative rather than 
quantitative heroin metabolism. It was therefore decided that the use of frozen tissue was 
acceptable for further studies. However, a wide variety of chemically diverse compounds is 
available that can provide cryoprotection to proteins [108], and this approach could be 
considered for future studies.  
 
4.2 Esterases metabolizing heroin in different organs 
Heroin metabolism in liver, brain and lung tissue was investigated in vitro to establish 
concentration-versus-time graphs and to identify the enzymes involved by the use of 
inhibitors.  
 
In liver and lung tissue the results showed that the specific CE inhibitors benzylisatin [49]and 
BNPP [60] significantly inhibited the hydrolysis of heroin. Cholinesterase inhibitors showed 
less effect. This suggests the involvement of CE. 100 µM but not 10 µM of iso-OMPA gave 
also a significant effect in liver and lung. Even though often considered a specific BChE 
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inhibitor [58, 79, 80], iso-OMPA has also shown activity towards CE [81-84]. One study 
found that 10 µM iso-OMPA inhibited a negligible amount of CE (5%) while 100 µM iso-
OMPA inhibited 50% of CE in perfused rat liver [114]. It thus seems reasonable to infer that 
the result in liver and lung could be caused by inhibition of CE activity. In agreement with 
these findings, Berry et al. [96] found that the activity of CE in rat liver was high while 
cholinesterase activity was not detectable.   
 
In brain tissue, the results showed that the specific AChE inhibitor Bw284c51 [70, 71], the 
specific BChE inhibitor ethopropazine [77, 115] and the general cholinesterase inhibitor 
neostigmine [65, 67] significantly inhibited heroin metabolism. There were no significant 
results for CE inhibitors. This suggests the involvement of cholinesterases, and that both 
AChE and BChE are involved in the heroin metabolism in rat brain.  
 
To investigate the tissue specific contribution to heroin metabolism in vivo, it is relevant to 
compare the in vitro results from liver, lung and brain tissue with heroin metabolism in blood. 
Bogen et al. have studied heroin metabolism in rat blood using the same methods as used in 
this thesis. These results can be found in the appendix 7.1 (unpublished data) and show a 
significant inhibition of heroin metabolism by CE inhibitors and iso-OMPA, suggesting that it 
is mainly CE which metabolize heroin in rat blood. This is in accordance with Berry et al. 
[96] who found that CE are the esterase enzyme with highest activity in rat blood. 
 
The results from these inhibitor studies show that different enzymes are responsible for 
metabolizing heroin in different tissues. Additionally the heroin metabolism concentration-
versus-time graphs presented in section 3.2 showed that the metabolism in liver was 
significantly faster compared to brain and lung. Boix et al [30] have previously found that the 
rate of heroin metabolism is slower in brain compared to blood. Consequently, it seems as CE 
in blood and liver is the major contributor to hydrolysis of heroin in vivo and is central in the 
metabolism of heroin in rat. However, hydrolysis in tissues other than blood may have 
different degrees of importance in vivo depending on the route of administration.  
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4.3 Localization of esterases metabolizing heroin in liver fractions 
The cellular localization of the enzymes responsible for heroin metabolism in rat liver was 
investigated. This was done by using three different liver fractions: microsomes which are 
derived from the endoplasmic reticulum, cytosol which is the intracellular fluid and s9 which 
contain both cytosol and microsomes. To our knowledge the use of liver fractions to study 
heroin metabolism has not been done previously. As rat and human liver fractions can be 
bought commercially, this is a convenient way of investigating the metabolism of drugs. This 
study was thus also an attempt to establish a new method of studying the metabolism of 
heroin in vitro. 
 
The results indicated that all the liver fractions studied were capable of hydrolyzing heroin to 
6MAM and further to morphine to some extent. However, in microsomes heroin was 
completely hydrolyzed to 6MAM twice as fast as compared to s9 and twelve times faster 
compared to cytosol. This indicates that esterases located in the microsomal fraction of the 
liver are more abundant and/or more efficient in hydrolyzing heroin. This observation is in 
agreement with previous work [116, 117] where liver CE has been found to be localized on 
the luminal surface of the endoplasmic reticulum membrane. 
 
However, establishing this method was associated with some challenges. The total level of 
heroin and heroin metabolites in microsomes and s9 was severely reduced (approximately 
60%) during the experiment. This happened to a lesser extent in cytosol where only a 
reduction of approximately 7% was observed. Several control experiments were carried out to 
investigate whether this could be caused by metabolites binding to the plastic in the 
experimental tubes or being captured in the pellet, or whether the metabolites were degraded 
by the precipitation method. All these hypotheses were negative. It was then speculated if 
6MAM and/or morphine was converted to a metabolite that was not included in the chosen 
experimental setup. Consequently, a time-of-flight mass spectrometry was carried out to 
analyze all molecules present in the sample simultaneously. The result showed the presence of 
nor-morphine, which may explain the loss of metabolites, as morphine can be N-demethylated 
by hepatic CYP3A4 and CYP2C8 to nor-morphine [32]. In microsomes and s9 these enzymes 
are abundant [118]. This may lead to a larger degree of CYP metabolism of morphine in 
microsomes and s9 compared to cytosol where these enzymes are not present. Additionally, 
UDPGA is a cofactor necessary for optimal glucuronidation by UGT [119, 120], the enzyme 
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responsible for metabolizing morphine [32]. This cofactor lacks in the microsomal and s9 
fractions [121] possibly causing morphine metabolism by UGT to be unable to compete with 
the CYP enzyme pathway. The lack of UDPGA could explain why a similar reduction in 
metabolites was not seen in crude liver homogenate. Unfortunately, it was not possible within 
the time frame of this thesis to establish a method to quantify the nor-morphine content of the 
samples. For further studies UDPGA could be added to the enzyme assay for microsomes and 
s9 to achieve optimal UGT activity and hence resemble physiological conditions.  
 
4.4 Inhibition of heroin metabolism in vivo  
A behavioral test measuring locomotor activity, combined with measurements of heroin 
metabolites in blood and brain tissue were used to assess the effect of esterase inhibitors on 
the heroin metabolism in vivo. The aim was to reduce the brain levels of the potent heroin 
metabolite 6MAM.  
 
The locomotor activity test is a well-established model for investigating the acute stimulating 
effects of different drugs [122, 123]. Administration of heroin, with a following increase in 
dopamine release in the nucleus accumbens, is known to produce an immediate dose-
dependent increase in locomotor activity [18]. In C57BL/6-mice, the immediate rise in 
locomotor activity after heroin administration is mediated by 6MAM, while morphine is 
involved later in the response [27, 30].  
 
In the first experiment, heroin was administrated s.c. which has been the main administration 
method of choice in previous studies of heroin effects [27, 124, 125]. The results from this 
experiment showed significantly higher concentrations of 6MAM in both blood and brain 
after pre-treatment with the inhibitor iso-OMPA. However, there were no measured changes 
in locomotor activity for these animals. Since the aim was to inhibit the enzymatic reaction 
from heroin to 6MAM, with the objective to reduce 6MAM levels in the brain the result was 
opposite of what was expected. This could be caused by the s.c. administration of heroin, 
which could subject the drug to increased peripheral metabolism at the injection site [126] so 
that heroin already was metabolized to 6MAM before entering the bloodstream and reacting 
with the enzyme inhibitor. Hence, the inhibitor seems to have acted on the second step of the 
heroin metabolism, impeding the transition of 6MAM to morphine. To circumvent the 
peripheral metabolization, the administration route of heroin was changed to i.v. injection in 
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the following experiment. This resulted in no significant differences in concentration of 
heroin metabolites in the brain for any of the pre-treatments with inhibitors, only in blood.  
 
Some of the mice administered the AChE inhibitor Bw284c51 displayed a significant 
reduction in locomotor activity. The mice showed typical signs of cholinergic syndrome, 
including whole body tremors and prostration. This is a condition caused by accumulation of 
excessive levels of acetylcholine [127], and was probably caused by the inhibitor. 
 
Since the effect of heroin is mediated through the presence of active metabolites in the brain 
[29], the results showed that the esterase inhibitors had no clear effect on the biological 
response of heroin in vivo. This could be caused by the mainly competitive mechanism of the 
enzyme inhibitors [39]. Because the substrate and inhibitor compete for binding to the 
catalytic site of the enzyme, this type of inhibition can be overcome by a high substrate 
concentration. It is also possible that the esterases have a greater affinity for heroin than the 
inhibitors, which would further favor hydrolysis of heroin. Therefore, it might not be possible 
to reach concentrations high enough to affect heroin metabolism in vivo with these enzyme 
inhibitors, at least not without having toxic side effects. A non-competitive inhibitor could 
possible work better to decrease the concentration of 6MAM, since such an inhibition is not 
affected by substrate concentration. 
 
Other studies using iso-OMPA [62, 82, 84] and BNPP [128, 129] in the same or lower 
concentrations in vivo have successfully measured significant inhibition of the activity of 
esterase enzymes in blood and/or brain.  However, even though the experimental conditions 
are quite similar, they are different in one or more important factors such as the time intervals 
following pre-treatment with inhibitor, administration method of inhibitor and/or different 
experimental species. For BW284c51 the literature is even less conclusive about doses 
measured to inhibit AChE in mice in vivo. Therefore, for further studies the enzyme activity 
could be determined by sampling blood from mice to assess whether the esterase inhibition is 
successful. This can be done by for example microtiter plate-based assay [114] for CE and the 
Ellman method for BChE and AChE [130] which are both established methods.  
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4.5 Species differences in heroin metabolism 
Some of the advantages of the use of rodents as a model for drug development are a metabolic 
pathway similar to humans and numerous similar anatomical and physiological characteristics 
[91]. However, both the rate of drug metabolism and the metabolites formed may differ 
between animal species. The main reasons for these discrepancies include different metabolic 
capacity and different enzyme activity [131]. It is thus important to identify these factors 
when using rodents to predict the metabolism of a drug in humans. 
 
The activity of CE in the liver is similar in rodents and humans [96]. In agreement with our 
results from rat liver, human hCE-1 and in part hCE-2 is present in the human liver and is 
capable of deacylating heroin to 6-MAM [97, 132, 133]. However, our results indicated that 
AChE was taking part in the metabolism of heroin in rat brain, while Salmon et. al (41) found 
that the human brain synaptic form of AChE was not capable to hydrolyze heroin and 6MAM 
to morphine. Rats and mice are also known to have high activity of CE in plasma [96, 134, 
135] and this enzyme is thought to hydrolyze heroin to 6MAM. Human plasma contains 
mostly BChE [96, 136] and in human blood the hydrolysis of heroin is thought to be 
catalyzed by erythrocyte AChE and serum BChE [31]. Blood erythrocyte AChE is found 
capable of further hydrolyzing 6MAM to morphine, while BChE is not [31].   
 
4.6 Potential pharmacokinetic treatment strategies for heroin addiction 
When looking for pharmacokinetic treatment options for heroin addiction, the aim is to reduce 
the rapid and high brain concentration of the first heroin metabolite 6MAM. This is 
challenging due to the extremely fast conversion from heroin to 6MAM, and then the much 
slower conversion of 6MAM to morphine. This renders high blood levels of the dominant 
active metabolite 6MAM to cross the blood-brain barrier and exhibit its strong rewarding and 
addictive effect in the brain [27]. By hindering the rewarding effect of the drug, it may be 
possible to support a change in behavior which could lead to recovery. 
In this thesis it was investigated if a reduced 6MAM concentration could be achieved by 
inhibiting the hydrolysis from heroin to 6MAM. The results indicate that this is associated 
with some challenges. However, there are several alternative pharmacokinetic approaches to 
reduce the levels of 6MAM in the brain. One possible alternative is to act directly on 6MAM 
itself by blocking its actions or to speed up the clearance of 6MAM from the body. The first 
possibility is already being studied by developing antibodies which binds to 6MAM and 
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thereby restrict its entry into the brain [137-140]. Another possibility is to increase the 
metabolism of 6MAM to morphine by adding enzymes with increased catalytic efficiency. In 
human blood AChE is found to hydrolyze 6MAM to morphine at the low rate of 0.1 
nmol/min (Salmon et al. 1999). Increasing this metabolism could hinder the accumulation of 
high levels of 6MAM. This option is already being studied in cocaine treatment with mutant 
enzymes [141-143]. The fact that cocaine, heroin and probably 6MAM are metabolized by the 
same esterase enzymes [144] indicates that such a pharmacokinetic approach could also be a 
possible strategy for the treatment of heroin addiction. 
 
5. Conclusions  
Heroin metabolism appears to be catalyzed mainly by AChE and BChE in rat brain and by CE 
in rat lung and liver. The calculated half-lives show that brain and lung tissue has significantly 
less capacity to hydrolyze heroin compared to liver. Several esterase inhibitors produced high 
grades of inhibition of the heroin metabolism in vitro; however these results were not 
reproduced in vivo. This could be because higher concentrations of the inhibitors are needed 
to significantly inhibit the enzymes. At this initial stage enzyme inhibition as a strategy to 
reduce the levels of the potent metabolite 6MAM seems challenging. Increased knowledge of 
the enzymes involved in metabolism of heroin is important and could thus lead to other 
pharmacokinetic treatment approaches, such as increased heroin metabolism by addition of 
mutant enzymes.
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7. Appendix 
7.1 Inhibitor studies of heroin metabolism in rat blood 
Bogen et al. have studied heroin metabolism in absence and presence of esterase inhibitors in 
rat blood (unpublished results) using the same methods as used in this master thesis. These 
results are included to be able to compare heroin metabolism in blood with liver, lung and 
brain tissue. The enzyme inhibitor experiments in rat blood were conducted as described in 
materials and methods section 2.4.4 with some modifications: The blood was fresh and was 
diluted 1:3 in NaCl and the incubation time was 3 min. The results are shown in figure 7.1 
and 7.2.  
 
 
            Figure 7.1. Concentrations of heroin, 6MAM and morphine in rat blood after addition of 
heroin (0.4 μM) in vitro in the presence of the cholinesterase inhibitors (10 µM or 100 µM); 
BW (BW284c51), ETZ (ethopropazine), Iso (iso-OMPA) and Neo (neostigmine). The 
incubation time was 3 min. Values significantly different from the control are indicated with 
asterisks (*p value<0.05, **p value<0.01, ***p value<0.001). All values are presented as 
mean ± SEM, n =3-6. Tested for significance by univariate General Linear Model. Each 
metabolite analyzed separately. Tukey’s test was used as a post-hoc test. 
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Figure 7.2. Concentrations of heroin, 6MAM and morphine in rat blood after addition of heroin (0.4 
μM) in vitro in the presence of the CE inhibitors (10 µM or 100 µM); Bn-isatin (benzylisatin) and 
BNPP. The incubation time was 3 min. Values significantly different from the control are indicated 
with asterisks (*p value<0.05, **p value<0.01, ***p value<0.001). All values are presented as mean 
± SEM, n =3-4. Tested for significance by univariate General Linear Model. Each metabolite 
analyzed separately. Tukey’s test was used as a post-hoc test. 
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7.2 LC-MS/MS conditions 
HPLC conditions 
Water alliance 2695 HPLC Pump Conditions: 
Injection volume: 10 μl 
Mobile phase: Methanol (A) 
5 mM ammonium formate buffer, pH 3.1 (B) 
Column: Xterra
®
 MS C18 (2.1 mm x 150 mm) 
Flow rate: 0.2 ml/min 
Column temperature:  0˚C 
Run time: 16 min 
Software: Mass Lynx 
 
Table 7.1 - HPLC pump gradient timetable 
Time 
(min) 
A % B % Flow 
0.00 3.0 97.0 0.200 
8.00 60.0 40.0 0.200 
10.00 60.0 40.0 0.200 
10.00 3.0 97.0 0.300 
16.00 3.0 97.0 0.300 
 
MS/MS-conditions 
MS detection was performed on a Quattro Premier XE tandem quadrupole MS. Ionization 
was achieved using electrospray in the positive mode (ESI+) and multiple reactions 
monitoring (MRM) was used for quantification  The source block temperature was 120˚C and 
the capillary voltage was 2 kV  The cone gas (N2) was heated up to 400 ˚C and the flow was 
set to 50 L/h. The desolvation gas (N2) was delivered at flow 900 L/h. 
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Table 7.2 - LC-MS/MS method 
Substance Rt 
(min) 
MRM 1 
(m/z) 
MRM 2 
(m/z) 
Cone 
voltage(V) 
Collision 
energy (eV) 
M3G 2.7 462.0 >286.0 462.0 >268.0 45 30/30 
Morphine 4.6 286.0 >201.0  45 20 
6MAM 8.1 328.0 >211.0  45 25 
Heroin 9.6 370.0 >268.0  50 30 
Internal  
standard 
     
M3G-d3 2.7 465.0 > 289.0  50 30 
Morphine-d6 4.6 292.0 > 201.0  45 25 
6MAM-d6 8.1 334.0 > 211.0  45 25 
Heroin-d9 9.6 379.0 > 272.0  45 28 
     
 
Table 7.3 – The limits of detection (LOD) and the limits of quantitation (LOQ) 
 
(LOQ) Heroin 6MAM Morphine M3G 
LOD 
Blood (mg/L)  
0.00096 0.00033 0.00049 0.0065 
LOQ 
Blood (mg/L) 
0.0025 0.00065 0.0012 0.019 
LOD 
Brain tissue 
(μg/g) 
0.0029 0.0010 0.0015 0.020 
LOQ 
Brain tissue 
(μg/g) 
0.0077 0.0022 0.0036 0.059 
 
 
 
